PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.06%
EBIT growth below 50% of GNPX's 39.46%. Michael Burry would suspect deeper competitive or cost structure issues.
7.06%
Operating income growth under 50% of GNPX's 39.46%. Michael Burry would be concerned about deeper cost or sales issues.
10.36%
Net income growth under 50% of GNPX's 39.46%. Michael Burry would suspect the firm is falling well behind a key competitor.
28.30%
EPS growth at 50-75% of GNPX's 40.05%. Martin Whitman would suspect a lag in operational efficiency or a higher share count.
28.30%
Diluted EPS growth at 50-75% of GNPX's 40.29%. Martin Whitman would question if share issuance or modest net income gains hamper progress.
24.68%
Share count expansion well above GNPX's 1.05%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
24.68%
Diluted share count expanding well above GNPX's 1.34%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
17.79%
OCF growth above 1.5x GNPX's 4.89%. David Dodd would confirm a clear edge in underlying cash generation.
17.79%
FCF growth above 1.5x GNPX's 4.63%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19298.96%
Negative 10Y OCF/share CAGR while GNPX stands at 22.15%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-3628.66%
Negative 5Y OCF/share CAGR while GNPX is at 22.15%. Joel Greenblatt would question the firm’s operational model or cost structure.
45.61%
3Y OCF/share CAGR above 1.5x GNPX's 22.15%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-15204.15%
Negative 10Y net income/share CAGR while GNPX is at 81.84%. Joel Greenblatt sees a major red flag in long-term profit erosion.
97.68%
5Y net income/share CAGR 1.25-1.5x GNPX's 81.84%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
59.13%
3Y net income/share CAGR 50-75% of GNPX's 81.84%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
9892.41%
Equity/share CAGR of 9892.41% while GNPX is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
293.35%
Equity/share CAGR of 293.35% while GNPX is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
201.29%
Equity/share CAGR of 201.29% while GNPX is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
67.39%
Asset growth above 1.5x GNPX's 25.66%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
64.49%
BV/share growth above 1.5x GNPX's 8.08%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
No Data
No Data available this quarter, please select a different quarter.
13.21%
We increase R&D while GNPX cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-38.56%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.